Mexico moves to increase regulatory efficiency, but prioritises generics
This article was originally published in Scrip
Executive Summary
Mexican authorities have introduced several new measures aimed at getting more drugs to the market more quickly. However, generic medicines manufacturers are most likely to benefit, because, as Mikel Arriola, commissioner of the health protection agency, COFEPRIS, recently told local companies, such products are the government's top priority.